common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, PK, and PD of single and multiple ascending SC doses of CB4211 in healthy non obese subjects and subjects with NAFLD.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - CB4211 Dose 1

Administered by subcutaneous injection

Drug - CB4211 Dose 2

Administered by subcutaneous injection

Drug - CB4211 Dose 3

Administered by subcutaneous injection

Drug - CB4211 Dose 4

Administered by subcutaneous injection

Drug - CB4211 Dose 5

Administered by subcutaneous injection

Drug - CB4211 Dose 6

Administered by subcutaneous injection

Drug - CB4211 Dose TBD

Administered by subcutaneous injection

Drug - Placebo

Administered by subcutaneous injection

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

common.study.values.clinical-trial-id

NCT03998514

participant.views.study.view.id

aADEle